Industry reports
Editor highlights

Multiple Sclerosis - Pipeline Review, H2 2011

World Pathology: Multiple Sclerosis - Pipeline Review, H2 2011

Global Markets Direct
  • Publication date: September 2011
  • Report price: $ 500

Get this report today!

$ 500 - 1 User License
$ 1 000 - Site License
$ 1 500 - Corporate License

Summary

Table of Contents

Data Series

Multiple Sclerosis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, H2 2011', provides an overview of the Multiple Sclerosis therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. 'Multiple Sclerosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Multiple Sclerosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Markets Direct
  • Publication date: September 2011
  • Report price: $ 500

Get this report today!

$ 500 - 1 User License
$ 1 000 - Site License
$ 1 500 - Corporate License

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Global Pathology Industry : Latest Reports

PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • December 2013
  • by Global Data

PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, ...

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...

What next for Health in Food? Consumer Lifestyles, Nutrition, Food Labelling and Product Choice

What next for Health in Food? Consumer Lifestyles, Nutrition, Food Labelling and Product Choice

  • $ 7 995
  • Industry report
  • January 2014
  • by Canadean Ltd

Product Synopsis Disease-related, demographic, and desire-led drivers are making health of growing importance to food marketers. However, barriers such as cost, habits, and confusion over how to eat healthily ...


Global Pathology Industry : Latest Downloads

Pharmaceutical : Innovation and Technology Trends

  • Industry report
  • March 2014
  • 42 pages

Cardiovascular Disease Sector Analysis

  • Industry report
  • February 2014
  • 75 pages

... New congenital heart disease review what matters a commitment to research ensures that services are continually focussed on improvement and development, so networks will be required to have ...

Pharmaceutical Market Overview

  • Industry report
  • February 2014
  • 34 pages
  • by Trade Association

... Conditions back pain musculoskeletal injuries stress minor illnesses the most common causes of short-term absence in non-manual workers (%) source bupa jan 2013 absence statistics 0 20 40 60 80 100 ...


ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.